Does the media prefer LGND or ADMA?

In the previous week, Ligand Pharmaceuticals had 7 more articles in the media than ADMA Biologics. MarketBeat recorded 13 mentions for Ligand Pharmaceuticals and 6 mentions for ADMA Biologics. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat ADMA Biologics' score of 0.50 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ANIP or LGND?

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 13 articles in the media. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat ANI Pharmaceuticals' score of 0.35 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Ligand Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UTHR or LGND?

In the previous week, United Therapeutics had 13 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 26 mentions for United Therapeutics and 13 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat United Therapeutics' score of 0.46 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ligand Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GMAB or LGND?

In the previous week, Ligand Pharmaceuticals had 10 more articles in the media than Genmab A/S. MarketBeat recorded 13 mentions for Ligand Pharmaceuticals and 3 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.86 beat Ligand Pharmaceuticals' score of 0.51 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LGND or BBIO?

In the previous week, BridgeBio Pharma had 23 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 36 mentions for BridgeBio Pharma and 13 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat BridgeBio Pharma's score of 0.49 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 7 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Ligand Pharmaceuticals (LGND) Competitors

$291.77 -2.83 (-0.96%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$291.83 +0.06 (+0.02%)

As of 04:56 AM Eastern

Compare

LGND vs. ADMA, ANIP, UTHR, GMAB, and BBIO

Should you buy Ligand Pharmaceuticals stock or one of its competitors? Ligand Pharmaceuticals's main competitors and comparable companies include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), United Therapeutics (UTHR), Genmab A/S (GMAB), and BridgeBio Pharma (BBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Ligand Pharmaceuticals (NASDAQ:LGND) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Ligand Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ligand Pharmaceuticals currently has a consensus price target of $335.75, suggesting a potential upside of 15.07%. ADMA Biologics has a consensus price target of $18.67, suggesting a potential upside of 99.86%. Given ADMA Biologics' higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Ligand Pharmaceuticals had 7 more articles in the media than ADMA Biologics. MarketBeat recorded 13 mentions for Ligand Pharmaceuticals and 6 mentions for ADMA Biologics. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat ADMA Biologics' score of 0.50 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 67.88% compared to ADMA Biologics' net margin of 32.98%. ADMA Biologics' return on equity of 40.17% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
ADMA Biologics	32.98%	40.17%	26.97%

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	21.70	$124.45M	$9.35	31.21
ADMA Biologics	$510.17M	4.10	$146.93M	$0.70	13.34

Summary

Ligand Pharmaceuticals beats ADMA Biologics on 11 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Ligand Pharmaceuticals has a net margin of 67.88% compared to ANI Pharmaceuticals' net margin of 11.07%. ANI Pharmaceuticals' return on equity of 27.37% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

Ligand Pharmaceuticals has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.98	$78.34M	$4.64	16.38
Ligand Pharmaceuticals	$268.09M	21.70	$124.45M	$9.35	31.21

ANI Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ANI Pharmaceuticals presently has a consensus price target of $105.83, indicating a potential upside of 39.25%. Ligand Pharmaceuticals has a consensus price target of $335.75, indicating a potential upside of 15.07%. Given ANI Pharmaceuticals' higher probable upside, equities analysts clearly believe ANI Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 13 articles in the media. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat ANI Pharmaceuticals' score of 0.35 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ligand Pharmaceuticals beats ANI Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, United Therapeutics had 13 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 26 mentions for United Therapeutics and 13 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat United Therapeutics' score of 0.46 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Ligand Pharmaceuticals has a net margin of 67.88% compared to United Therapeutics' net margin of 41.56%. United Therapeutics' return on equity of 20.18% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

United Therapeutics presently has a consensus target price of $646.00, suggesting a potential upside of 27.05%. Ligand Pharmaceuticals has a consensus target price of $335.75, suggesting a potential upside of 15.07%. Given United Therapeutics' higher possible upside, equities research analysts clearly believe United Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

United Therapeutics has higher revenue and earnings than Ligand Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.85	$1.33B	$27.95	18.19
Ligand Pharmaceuticals	$268.09M	21.70	$124.45M	$9.35	31.21

Summary

United Therapeutics beats Ligand Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Genmab A/S currently has a consensus price target of $39.50, indicating a potential upside of 20.28%. Ligand Pharmaceuticals has a consensus price target of $335.75, indicating a potential upside of 15.07%. Given Genmab A/S's higher possible upside, research analysts clearly believe Genmab A/S is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Genmab A/S has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ligand Pharmaceuticals had 10 more articles in the media than Genmab A/S. MarketBeat recorded 13 mentions for Ligand Pharmaceuticals and 3 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.86 beat Ligand Pharmaceuticals' score of 0.51 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 67.88% compared to Genmab A/S's net margin of 19.08%. Ligand Pharmaceuticals' return on equity of 20.06% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

Genmab A/S has higher revenue and earnings than Ligand Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.50	$963M	$1.27	25.86
Ligand Pharmaceuticals	$268.09M	21.70	$124.45M	$9.35	31.21

Summary

Ligand Pharmaceuticals beats Genmab A/S on 11 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to BridgeBio Pharma?

Ligand Pharmaceuticals (NASDAQ:LGND) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Ligand Pharmaceuticals has a net margin of 67.88% compared to BridgeBio Pharma's net margin of -97.03%. Ligand Pharmaceuticals' return on equity of 20.06% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Ligand Pharmaceuticals has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ligand Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	21.70	$124.45M	$9.35	31.21
BridgeBio Pharma	$713.07M	21.90	-$724.93M	-$3.57	N/A

Ligand Pharmaceuticals currently has a consensus price target of $335.75, suggesting a potential upside of 15.07%. BridgeBio Pharma has a consensus price target of $100.79, suggesting a potential upside of 26.16%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, BridgeBio Pharma had 23 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 36 mentions for BridgeBio Pharma and 13 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat BridgeBio Pharma's score of 0.49 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	7 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ligand Pharmaceuticals beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

Get Ligand Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGND vs. The Competition

Export

Metric	Ligand Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.87B	$3.73B	$7.03B	$13.06B
Dividend Yield	N/A	3.69%	2.56%	10.62%
P/E Ratio	31.21	11.49	270.82	25.39
Price / Sales	21.70	1,304.54	606.78	92.24
Price / Cash	37.52	45.11	28.87	38.47
Price / Book	5.65	17.44	11.18	6.51
Net Income	$124.45M	-$13.18M	$3.45B	$347.22M
7 Day Performance	1.05%	0.82%	0.59%	1.27%
1 Month Performance	-3.83%	2.54%	2.07%	2.72%
1 Year Performance	90.38%	53.96%	61.58%	21.85%

Ligand Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGND Ligand Pharmaceuticals	3.7855 of 5 stars	$291.77 -1.0%	$335.75 +15.1%	+93.1%	$5.87B	$268.09M	31.21	80
ADMA ADMA Biologics	3.8194 of 5 stars	$9.47 +0.6%	$18.67 +97.1%	-45.0%	$2.19B	$512.28M	13.53	530
ANIP ANI Pharmaceuticals	4.3337 of 5 stars	$76.54 +2.4%	$105.83 +38.3%	-13.1%	$1.74B	$883.37M	16.50	600
UTHR United Therapeutics	4.0234 of 5 stars	$499.73 -0.3%	$646.00 +29.3%	+62.4%	$21.43B	$3.15B	17.88	1,400	Insider Trade Analyst Revision
GMAB Genmab A/S	4.207 of 5 stars	$31.94 +1.9%	$39.50 +23.7%	+40.9%	$19.92B	$3.72B	25.15	3,029

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGND) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, UTHR, GMAB, and BBIO

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Summary

How does Ligand Pharmaceuticals compare to Genmab A/S?

Summary

How does Ligand Pharmaceuticals compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, UTHR, GMAB, and BBIO

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Which has more volatility and risk, LGND or ADMA?

Do insiders and institutionals have more ownership in LGND or ADMA?

Do analysts prefer LGND or ADMA?

Does the media prefer LGND or ADMA?

Is LGND or ADMA more profitable?

Which has better valuation & earnings, LGND or ADMA?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Is ANIP or LGND more profitable?

Which has preferable valuation & earnings, ANIP or LGND?

Which has more volatility & risk, ANIP or LGND?

Do insiders & institutionals have more ownership in ANIP or LGND?

Do analysts rate ANIP or LGND?

Does the media refer more to ANIP or LGND?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Do insiders & institutionals have more ownership in UTHR or LGND?

Does the media favor UTHR or LGND?

Which has more volatility & risk, UTHR or LGND?

Is UTHR or LGND more profitable?

Do analysts prefer UTHR or LGND?

Which has higher valuation & earnings, UTHR or LGND?

Summary

How does Ligand Pharmaceuticals compare to Genmab A/S?

Do analysts rate GMAB or LGND?

Which has more volatility and risk, GMAB or LGND?

Do institutionals & insiders have more ownership in GMAB or LGND?

Does the media favor GMAB or LGND?

Is GMAB or LGND more profitable?

Which has better valuation & earnings, GMAB or LGND?

Summary

How does Ligand Pharmaceuticals compare to BridgeBio Pharma?

Is LGND or BBIO more profitable?

Which has more risk & volatility, LGND or BBIO?

Do insiders & institutionals hold more shares of LGND or BBIO?

Which has preferable earnings and valuation, LGND or BBIO?

Do analysts recommend LGND or BBIO?

Does the media prefer LGND or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools